Targeting cancer stem cells in drug discovery: Current state and future perspectives

doi:10.4252/wjsc.v11.i7.398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13880)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

1182

WORD

425

HTML

9138

Figures (1-5)

192

Tables (1-3)

200

Sum=11137

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

277

Download

555

Sum=832

Publishing Process of This Article

Item

Count

Browse

729

Download

1182

Sum=1911

Jul 26, 2019 (publication date) through May 25, 2024

Times Cited of This Article

Times Cited (66)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2019; 11(7): 398-420
Published online Jul 26, 2019. doi: 10.4252/wjsc.v11.i7.398

Table 3 Agents targeting the Smoothened protein in clinical development

Compound	Target/mechanism	Cancer type	Highest phase	Organization
Vismodegib (GDC-0449)	Smo	Basal cell carcinoma	Launched	Roche
Sonidegib (NVP-LDE225)	Smo	Basal cell carcinoma	Launched	Novartis
Glasdegib	Smo	AML	Launched	Pfizer
Patidegib	Smo	Basal cell nevus syndrome; skin cancer	Phase II	PellePharm
BMS-833923	Smo	Leukemia	Phase II	Bristol-Myers Squibb
Taladegib	Smo	Esophageal cancer; gastroesophageal junction cancer; solid tumors; small cell lung carcinoma	Phase I/II	Ignyta
G-024856	Smo	Basal cell carcinoma	Phase I	Roche
LEQ-506	Smo	Advanced solid tumors	Phase I	Novartis

Smo: Smoothened.

Citation: Du FY, Zhou QF, Sun WJ, Chen GL. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World J Stem Cells 2019; 11(7): 398-420
URL: https://www.wjgnet.com/1948-0210/full/v11/i7/398.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i7.398